<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36397">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632721</url>
  </required_header>
  <id_info>
    <org_study_id>1315.2</org_study_id>
    <secondary_id>2015-002892-30</secondary_id>
    <nct_id>NCT02632721</nct_id>
  </id_info>
  <brief_title>A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>An Open-label, Phase I/II Trial to Determine the Maximum Tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 836858 in Combination With Decitabine in Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Phase I Dose Escalation: Primary objective is to determine the MTD and the recommended dose
      for Phase I Extension. Secondary objective is to investigate the safety, pharmacokinetics
      and efficacy of BI 836858 in combination with decitabine Phase I Extension: Primary
      objective is to collect additional data on safety, pharmacokinetics and efficacy and to
      define the Recommended Phase II Dose (RP2D) of BI 836858 in combination with decitabine.

      Phase II: Primary objective is to investigate efficacy, safety and pharmacokinetics of BI
      836858 in combination with decitabine compared to decitabine monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Number of patients with dose limiting toxicity (DLT(s)) during first treatment cycle</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II:Number of patients with objective response combining - Complete remission (CR) - CR with incomplete blood count recovery (CRi)</measure>
    <time_frame>30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: MTD of BI 836858 in combination with decitabine</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: - Event free survival (EFS)</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: - Relapse free survival (RFS)</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: - Remission duration</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: - Time to remission</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Number of patients with objective response combining - Complete remission (CR) - CR with incomplete blood count recovery (CRi)</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Cohorts (Phase I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination treatment of decitabine with escalating doses of BI 836858</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension Cohorts (Phase I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination treatment of decitabine with BI 836858 at MDT (Maximum Tolerated Dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1 (Phase II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination treatment of decitabine with BI 836858 at R2PD (Recommended Phase II dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (Phase II)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Monotherapy treatment with decitabine (standard of care treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <arm_group_label>Dose Escalation Cohorts (Phase I)</arm_group_label>
    <arm_group_label>Extension Cohorts (Phase I)</arm_group_label>
    <arm_group_label>Arm 1 (Phase II)</arm_group_label>
    <arm_group_label>Arm 2 (Phase II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836858</intervention_name>
    <description>BI 836858 weekly i.v. infusion</description>
    <arm_group_label>Dose Escalation Cohorts (Phase I)</arm_group_label>
    <arm_group_label>Extension Cohorts (Phase I)</arm_group_label>
    <arm_group_label>Arm 1 (Phase II)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Phase I Dose Escalation:

               1. Male or female patients &gt;/= 18 years of age with relapsed or refractory AML

               2. Male or female patients &gt;/= 65 years of age with previously untreated AML
                  ineligible for receiving standard intensive therapy

          -  Phase I Extension and Phase II:

        Male or female patients &gt;/= 65 years of age with previously untreated AML ineligible for
        receiving standard intensive therapy

          -  Histologically or cytologically confirmed AML according to the WHO classification

          -  Patients must be eligible for treatment with decitabine

          -  Eastern co-operative oncology group (ECOG) performance score &lt;/=2 at screening
             Further inclusion criteria apply

        Exclusion criteria:

          -  Acute promyelocytic leukemia (APL, French-American-British (FAB) subtype M3),
             according to WHO classification.

          -  Patients who are candidates for allogeneic stem cell transplantation.

          -  Active chronic graft versus host disease requiring immunosuppressive treatment.

          -  Phase I extension and Phase II only: Prior treatment with a hypomethylating agent,
             such as prior treatment for MDS.

          -  Prior treatment with Cluster of differentiation 33 (CD33) antibody Furthr exclusion
             criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>December 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
